Breaking Finance News

Zogenix, Inc. (NASDAQ:ZGNX) target bumped up to $16.00, released a ratings update earlier today by Zacks Investment Research

Yesterday Zogenix, Inc. (NASDAQ:ZGNX) traded 0.99% higher at $14.65. The company’s 50-day moving average is $13.43 and its 200-day moving average is $11.75. The last closing price is up -12.79% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time period. 152,775 shares of the stock traded hands, down from an average trading volume of 236,681

Zacks Investment Research upped the price target of Zogenix, Inc. (NASDAQ:ZGNX) to $16.00 indicating a possible upside of 0.09%.

See Chart Below

Zogenix, Inc. (NASDAQ:ZGNX)

Zogenix, Inc. has a 52 week low of $7.50 and a 52 week high of $15.40 The company’s market cap is currently $0.

Brief Synopsis About Zogenix, Inc. (NASDAQ:ZGNX)

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.